Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000922527 | SCV001067961 | benign | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002320093 | SCV002608899 | likely benign | Cardiovascular phenotype | 2021-03-30 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003330997 | SCV004039156 | likely benign | not specified | 2023-08-01 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003903012 | SCV004725741 | likely benign | LPL-related disorder | 2019-10-28 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Natera, |
RCV001832083 | SCV002083226 | likely benign | Hyperlipoproteinemia, type I | 2019-10-25 | no assertion criteria provided | clinical testing |